Oncology 5,539 programs
- First People's Hospital · 474 programs · 53 late-stage
- Chinese Academy of · 400 programs · 70 late-stage
- United Therapeutics Europe · 219 programs · 43 late-stage
Intelligence · Clinical Development
Clinical Development Intelligence
Pipeline intelligence, regulatory progress, and competitive landscape — not a flat database. Track phase distribution, catalysts, and sponsor rankings across indexed programs.
Programs indexed 20,548
Sponsors 1,769
Drugs tracked 4,797
Quick answer
NovaPharmaNews Clinical Development Intelligence tracks 20,548 pharmaceutical pipeline programs from ClinicalTrials.gov with phase distribution, therapeutic area hubs, NDA/BLA watchlists, upcoming readouts, company rankings, and competitive landscape views — designed for BD, investor, and regulatory teams benchmarking against Evaluate Pharma, Citeline, and GlobalData.
Search pipeline intelligence
Latest indexed programs
Recent programs from the index — each links to a sponsor program profile with hub cross-links. Browse Phase III hub
-
1:1:1 Blood Transfusion Ratio
United Therapeutics Europe Ltd
Trauma
1 trial -
1mg elsunersen
Chongqing Precision Biotech Co., Ltd
Epileptic Encephalopathy
1 trial -
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
2 mg Melatonin
United Therapeutics Europe Ltd
Anxiety
1 trial -
2-mg Intravitreous Aflibercept Injection
Regeneron UK Limited
Proliferative Diabetic Retinopathy
1 trial -
2.0 mg intravitreal aflibercept
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
20 mg VEC-162
Vanda Pharmaceuticals Netherlands B.V.
Insomnia
1 trial -
20 mg sildenafil citrate by mouth
The First People's Hospital of Lianyungang
Pulmonary Hypertension
1 trial -
20-01/BetaSal-S
Alphapharm Pty Ltd
Chronic stable plaque psoriasis
1 trial -
20-AVP-786-306
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
2008-46
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.